McKesson's Q1 earnings show strength from oncology growth, GLP-1 momentum, and RxTS expansion. However, pricing reform and margin pressures pose risks. The stock has underperformed the broader market over the past year, but analysts remain highly optimistic about its prospects, suggesting it should be retained in portfolios for now.